Navigation Links
Webcast Alert: Isis Pharmaceuticals' Second Quarter 2013 Financial Results Conference Call
Date:7/29/2013

CARLSBAD, Calif., July 29, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast:What:

Isis Pharmaceuticals' Second Quarter 2013 Financial Results and Highlights Conference CallWhen:

Tuesday, August 6, 2013 at 11:30 a.m. ET / 8:30 a.m. PTWhere: 

www.isispharm.comHow:

Live on the Internet.  Simply log onto our website listed above. If you are unable to participate during the live event, a replay of the webcast will be available for a limited time at www.isispharm.com.

ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 28 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer.  Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO™, in the United States for the treatment of patients with HoFH.  Genzyme is also pursuing marketing approval of KYNAMRO in other markets.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

ISIS PHARMACEUTICALS' FORWARD-LOOKING STATEMENT
This press release includes forward-looking statements regarding Isis' business and the therapeutic potential of Isis' technologies and products in development.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs, including the commercial potential of KYNAMRO, is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2012, and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc.  Regulus Therapeutics™ is a trademark of Regulus Therapeutics Inc.  KYNAMRO™ is a trademark of Genzyme Corporation.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Thoratec Schedules First Quarter Conference Call, Webcast
2. Watson to Host Conference Call and Webcast to Discuss First Quarter 2012 Earnings
3. Henry Schein to Webcast First Quarter 2012 Conference Call Tuesday, May 8, at 10:00 a.m. EDT
4. STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast
5. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
6. Pro-Dex, Inc. Announces Fiscal 2012 Third Quarter Financial Results Conference Call and Webcast
7. Cempra, Inc. to Report First Quarter 2012 Financial and Operating Results, and Host Conference Call and Webcast on May 10, 2012
8. Heartware Schedules First Quarter Conference Call And Webcast
9. Volcano Corporation Presentation At JMP Securities Conference To Be Webcast
10. HeartWare Presentation at the Bank of America Merrill Lynch 2012 Health Care Conference to be Webcast
11. Ampio Pharmaceuticals Schedules 2012 Update Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... 2016 , Net Sales of $1.90 billion ... the prior year period, and an increase of 1.2% on ... EPS for the first quarter were $0.52 reported, a decrease ... an increase of 29.9% over the prior year period ... guidance for 2016 Zimmer Biomet Holdings, Inc. (NYSE ...
(Date:4/28/2016)... , April 28, 2016 TapImmune,Inc. ... of innovative peptide and gene-based immunotherapeutics and vaccines for the ... be presenting at the 3rd Annual Growth Capital Expo ... th , 2016 at Caesars Palace in Las Vegas, Nevada.  ... on Wednesday, May 4 th by Dr. John ...
(Date:4/27/2016)... --   , Total Sales ... Sales  Clinical sales grow 16% year-over-year  , ... OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary confocal laser ... quarter ended March 31, 2016 and provided an update ... strategy. First Quarter 2016 Revenue Results by ...
Breaking Medicine Technology:
(Date:4/28/2016)... ... April 28, 2016 , ... Trinity ... Tobacco-Free Kids, a leading force in the fight to reduce tobacco use and ... policies that can help reduce tobacco use. The initiative brings together two organizations ...
(Date:4/28/2016)... Illinois (PRWEB) , ... April ... ... the leading provider of enterprise Data Center Infrastructure Management solutions, announces today ... focuses on feature enhancements in the area of capacity management and optimization, ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... Aesthetic Surgery Education and Anzu®, developers of the AnzuMedical™ Knowledge Sharing and ... Surgery Collaborative Residency Network. The platform is scheduled to launch in July 2016 ...
(Date:4/28/2016)... ... April 28, 2016 , ... Accreditation Commission ... Oncology Pharmacy Association (COPA) to develop a comprehensive Specialty Pharmacy Accreditation with Distinction ... an accreditation distinction. ACHC provides a wide range of pharmacy accreditation services that ...
(Date:4/28/2016)... D.C. (PRWEB) , ... April 28, 2016 , ... The ... and Prevention (CDC) has established an ICD-10-CM code for sarcopenia, giving it recognition for ... the medical community effective October 1, 2016. , Sarcopenia is defined as a combination ...
Breaking Medicine News(10 mins):